SS-31
Last updated: January 20, 2026
For informational purposes only. Not medical advice. Always consult a healthcare professional.
Tried SS-31? Be part of the collective knowledge. Share your experience - your insights help others on their journey.
What Is SS-31?
SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane to reduce oxidative stress and improve mitochondrial function. It works by preventing mitochondrial dysfunction, reducing reactive oxygen species production, and maintaining mitochondrial membrane integrity. Primarily researched for kidney disease, cardiac dysfunction, neurodegenerative conditions, and age-related mitochondrial decline.
This is a peptide. Most peptides are research chemicals requiring reconstitution and subcutaneous injection. Purity and storage conditions matter.
Quick Verdict
This is not a supplement. SS-31 is a mitochondria-targeted peptide in active clinical trials for Barth syndrome and heart failure, with real institutional backing and a specific binding target: cardiolipin in the inner mitochondrial membrane. The Phase III trials for Barth syndrome narrowly missed primary endpoints despite showing biological activity, which raises questions about trial design as much as drug efficacy. Sentiment is 68/100 (Mixed) across 8 tracked studies.
Evidence Quality
- Human trials: Moderate (Phase II/III trials for Barth syndrome and heart failure; mixed primary endpoint results but biological activity confirmed)
- Animal evidence: Strong (consistent mitochondrial protection across multiple disease models)
- Community reports: Sparse (very limited self-experimentation community; difficult to source)
- Key uncertainty: Phase III trials for Barth syndrome narrowly missed primary endpoints despite showing biological activity, raising questions about trial design versus drug efficacy.
What the Research Shows
SS-31 is relevant primarily to people with diagnosed mitochondrial dysfunction or cardiomyopathy, not to healthy individuals seeking optimization. Research demonstrates significant therapeutic potential in kidney disease, improved mitochondrial dysfunction and memory impairment, and improved cardiac function in animal models. The peptide requires subcutaneous injection and is not commercially available as a supplement. Sourcing from research chemical suppliers means zero quality assurance.
Who Should Be Cautious
This is an investigational drug. Self-administration outside clinical trials carries unknown risks. Anyone considering it should weigh the absence of long-term safety data against the severity of their condition.
What This Page Cannot Tell You
Whether SS-31 provides any benefit to people with normal mitochondrial function is unknown and may never be studied, since clinical development is focused on disease states.
What Experts Say
You're not going to see RCTs of BPC or epithalon or SS31 or (fill in popular peptide) because (drum roll)… there is no patent opportunity or broad enough interest. People will keep experimenting & taking however. Just be careful if you do: avoid gray and market peptides folks!
SS-31 or elamipretide just got FDA approved as Forzinity. This is a mitochondrial tetrapeptide (4 amino acids) that is approved for this rare disease called Barth Syndrome with a defect in cardiolipin in mitochondria.
My favorite mitochondrial optimizers: Creatine, NMN, CoQ10, ALA, PQQ, L-Carnitine, TMG, Magnesium, NAC, B vitamins (B1, B2, B3, B5, B12), Metformin, Oxaloacetate, Methylene Blue, SS-31, MOTS-c
Quotes sourced from public posts on X or contributed exclusively to Dopamine Club. Views expressed are those of the original authors.
SS-31 Research & Studies
01 SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease ▸
SS-31 demonstrated significant therapeutic potential in kidney disease by reducing mitochondrial ROS production, preventing mitochondrial depolarization, and inhibiting mitochondrial permeability transition pore formation.
View Study (PubMed)02 Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice ▸
SS-31 successfully improved mitochondrial dysfunction and reversed memory impairment and synaptic damage caused by inflammatory stress in mice, demonstrating neuroprotective effects.
View Study (PubMed)03 Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice ▸
In vivo administration of SS-31 improved cardiac mitochondrial dysfunction and cardiolipin profiles in Barth Syndrome mice, showing promise for treating genetic mitochondrial disorders.
View Study (PubMed)04 Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease ▸
Review article highlighting SS-31's potential in treating metabolic and neurological disorders through inhibition of oxidative stress and restoration of mitochondrial function.
View Study (PubMed)05 SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model via Sirt3/Pgc-1α positive feedback loop ▸
SS-31 demonstrated therapeutic effects in migraine by restoring mitochondrial function and alleviating pain responses through the Sirt3/Pgc-1α pathway.
View Study (PubMed)06 Mitochondrial protein interaction landscape of SS-31 ▸
Cross-linking mass spectrometry revealed SS-31 interacts with proteins involved in ATP production and oxidative phosphorylation, providing mechanistic insights into its pharmacological effects.
View Study (PubMed)07 Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury ▸
SS-31 reduced mitochondrial oxidative damage and protected against tissue injury in ischemia-reperfusion models, demonstrating vascular protective effects.
View Study (PubMed)08 Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury ▸
SS-31 reduced neuronal death, tissue damage, and promoted behavioral recovery after spinal cord injury by preventing cardiolipin alterations and mitochondrial dysfunction.
View Study (PubMed)SS-31 User Reviews & Experiences
Sentiment score computed from aggregated public user reports, forums, and community discussions. Not a clinical measure.
Users report varied experiences with SS-31, with many experiencing improved energy and mitochondrial function at higher doses (5mg), while others find minimal effects at lower doses (2mg). Cost is a significant concern, and some users require the addition of methyl donors or NAD+ to avoid fatigue side effects.
SS-31 Benefits, Dosage & Side Effects
- Energy Enhancement: Users report smooth, sustained energy improvements without jittery feelings, particularly beneficial for workouts and daily activities
- Mitochondrial Repair: Multiple users note SS-31 appears to repair mitochondria over time, with effects that persist after cycling off
- Metabolic Increase: Some users observe increased metabolism and improved body composition when combined with exercise
- Recovery Improvement: Enhanced recovery from exercise and reduced fatigue reported by consistent users
- Dose-Dependent Response: Most users find minimal effects at 2mg daily but significant benefits at 5mg daily, suggesting higher doses are necessary for noticeable results
- Age Factor: Evidence suggests SS-31 is most effective for individuals over 50 years old, with younger users reporting less dramatic benefits
- Synergy Required: Many users find SS-31 works best when combined with MOTS-C, NAD+, or methyl donors (B12, TMG) rather than as a standalone peptide
- Timeline: Effects typically become noticeable after 2-4 weeks of consistent use, with some users reporting initial fatigue before experiencing benefits
- Standard Protocol: 5mg daily for 8 weeks is commonly reported as the effective dose for mitochondrial repair
- Maintenance Dosing: After initial 8-week cycle, users drop to 2-3mg three times per week or cycle with MOTS-C
- Low-Dose Experience: 2mg daily reported as minimally effective by most users, though some notice subtle metabolic changes
- High-Dose Protocol: Some users successfully run 5mg for 10 consecutive days as an intensive protocol before reducing to maintenance
- Initial Fatigue: Some users experience increased fatigue when starting SS-31, which may require supplementation with methyl donors or NAD+ to resolve
- Midday Sleepiness: Users in third month of continuous use report sleepiness that resolves by switching to nighttime dosing
- Minimal Side Effects: Most users report no negative side effects at standard doses when properly supported with cofactors
- Individual Variation: Effects vary significantly between individuals, with some experiencing no noticeable benefits despite proper dosing
- Cost Concern: SS-31 is consistently reported as expensive, particularly at the 5mg daily dose required for effectiveness
- Injection Required: Subcutaneous injection is the standard route, though some vendors offer intranasal sprays of questionable efficacy
- Research Chemical Status: Available from peptide suppliers as a research chemical, not FDA-approved for general use outside clinical trials
Related Compounds
Community Reviews
Share your experience with SS-31 and help others make informed decisions.
Write a Review
Sign in to leave a review